ngshrd | 906

HRD Assay

Keywords:

BRCA1

BRCA2

BRCAness

GIS

Genomic Instability Score

HRD

HRR

Homologous Recombination Deficiency

MyChoice

Myriad

Next Generation Sequencing

Next-Generation Sequenzierung

Ovarian cancer

Ovarian carcinoma

Status

Material

Tissue biopsy

Tube sterile, white (32)

Hint

Mutations in >50 genes associated with BRCAness (incl. BRCA1, BRCA2, PALB2) and evaluation of the Genomic Instability Score (GIS)(TruSight Oncology 500 HRD powered by Myriad) To order this analysis, please contact us via contact@viollier.ch or 0848 121 121. This analysis may result in excess information. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG shall arrange for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent). Tarification: according to Tarmed

Duration

14 days

Frequency

1 x per week

Method

Next Generation Sequencing